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Breast and cervical cancers have emerged as major global health challenges and dispro-
portionately lead to excess morbidity and mortality in low- and middle-income countries
(LMICs) when compared to high-income countries. The objective of this paper was to high-
light key findings, recommendations, and gaps in research and practice identified through a
scoping study of recent reviews in breast and cervical cancer in LMICs.
Methods
We conducted a scoping study based on the six-stage framework of Arskey and O’Malley.
We searched PubMed, Cochrane Reviews, and CINAHL with the following inclusion crite-
ria: 1) published between 2005-February 2015, 2) focused on breast or cervical cancer 3)
focused on LMIC, 4) review article, and 5) published in English.
Results
Through our systematic search, 63 out of the 94 identified cervical cancer reviews met our
selection criteria and 36 of the 54 in breast cancer. Cervical cancer reviews were more likely
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to focus upon prevention and screening, while breast cancer reviews were more likely to
focus upon treatment and survivorship. Few of the breast cancer reviews referenced
research and data from LMICs themselves; cervical cancer reviews were more likely to do
so. Most reviews did not include elements of the PRISMA checklist.
Conclusion
Overall, a limited evidence base supports breast and cervical cancer control in LMICs. Fur-
ther breast and cervical cancer prevention and control studies are necessary in LMICs.
Introduction
As a global health priority, cancer is rapidly emerging as a visible and prevalent challenge dif-
ferentially impacting low- and middle-income countries (LMICs) compared with high-income
countries (HICs) [1–4]. With substantial differences between HICs and LMICs regarding
health resources, environment, infrastructure, technology, and medical personnel, addressing
prevention and treatment of cancer in LMIC settings may require a different evidence base [5–
7]. Given the varying local resources and capacity, extrapolating from research conducted by
and for HICs could lead to inappropriate conclusions and strategies [8–10]. That said, for com-
plex non-communicable diseases like cancer, diagnosis and treatment can, similarly, be techni-
cally and medically complicated [3]. Making presumptions about the inability of LMICs to
adopt best-practices identified elsewhere is equally problematic [11] since relative success in
many LMICs with preventing and controlling other technically-intensive complex diseases like
HIV was perhaps more successful (in some logistical aspects) than initially expected [12]. An
evidence base developed within LMICs is necessary to inform optimal and effective care and
successful strategies for cancer control, while avoiding erroneous assumptions and extrapola-
tions from work done in high-income countries [13].
Though considerable regional variation exists, the cumulative probability of breast cancer
for women aged 15–79 years in less developed countries in 2010 was 3.8% (95% CI: 3.4–4.1),
closer to 50% higher than the rate from 1980 (2.4%; 95% CI: 2.1–2.9) [14]. The cumulative
probability of cervical cancer for women aged 15–79 years in less developed countries in 2010
was 1.2% (95% CI: 0.9–1.6), slightly lower than the rate in 1980 (2.6%; 95%CI:1.7–3.3).[14]
The cumulative probability of death from breast cancer for women aged 15–79 years in less
developed countries in 2010 was 2.1% (95%CI: 1.7–2.3) a two-fold increase from 1980 levels
(1.1%; 95% CI: 1.0–1.3) [14]. For cervical cancer the cumulative probability of death in 2010
was 0.5% (95%CI: 0.3–0.7) a third of what it was in 1980 (1.5%: 95% CI 1.0–1.9) [14]. Cancer
patterns globally are anticipated to continue shifting [15], as infection-related cancers begin to
decline and cancers relating to diet, lifestyle, and hormones increase, particularly in less devel-
oped countries [16].
To date, a wide range of systematic and non-systematic literature reviews have been con-
ducted examining breast and cervical cancer control in LMICs. The purpose of this paper was
to conduct a scoping study assessing the current status of published evidence for best practices
across the care continuum for breast and cervical cancer in LMICs and to identify common
themes and gaps that could be addressed with future research and systematic reviews. Specifi-
cally, the guiding research question was what reviews have indicated best practice for preven-
tion, screening, diagnosis, treatment, and survivorship for breast and cervical cancer in LMICs.
Researchers often undertake such “scoping studies” to examine the extent, range, and nature of
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research activity and identify gaps in the existing literature [17]. Given the wide range of study
designs utilized in LMICs, a scoping study—essentially a “reviews of reviews”—is ideal to ascer-
tain current evidence around breast and cervical cancer control in LMICs.
Methods
A scoping study of breast and cervical cancer control in LMICs was conducted following the
six-stage framework of Arskey and O’Malley [18] and the additional recommendations of
Levac et al. [17]. This type of methodological approach attempts to systematically locate litera-
ture and classify it, but does not aim to exclude studies based on methodological quality nor to
produce quantitative syntheses. Instead, scoping reviews aim to describe and summarize
research findings on a specific topic and to highlight research gaps. The six stages of the frame-
work and our specific methods are outlined below.
1. Research question
Following the recommendations of Levac et al. [17], we linked our research question (“What
reviews have indicated best practice for prevention, screening, diagnosis, treatment, and survivor-
ship for breast and cervical cancer in LMICs?”)with the purpose of the scoping study (“Identify
key themes, recommendations, and research/ practice gaps for breast and cervical cancer control
in LMICs”). Our primary interest was to examine the range of reviews on breast and cervical
cancers in LMICs and identify priority areas for future systematic reviews and future research
where the research base is lacking.
2. Identification of relevant studies
Searches in PubMed, Cochrane Review, and CINHAL were conducted with the following
inclusion criteria: 1) published between 2005-February 2015, 2) focus on women with breast
and cervical cancer, 3) focused on LMICs countries, 4) review article, and 5) published in
English language. Subsequently, the search strategy for breast cancer reviews in PubMed
included: ("Breast Neoplasms" (MeSH)) AND "Developing Countries" (MeSH); Filters: review;
published in the last 10 years). For cervical cancer searches breast cancer was replaced by
("Uterine Cervical Neoplasms"(MeSH)). For details on MeSH subheadings please see S1 Text.
In addition, “developing countries(MeSH)” was replaced by the keyword “low-income coun-
tries” and “low-income country” and unique reviews were included in the review. A few
reviews [n = 3] that were not initially detected in our search because they focused on specific
countries, or lacked a keyword match, but were identified by our research team as relevant to
our objective were included.
3. Study selection
Two members of the abstraction team reviewed each manuscript for two study selection crite-
ria: 1) a focus on cervical and breast cancer in LMICs, and 2) reflected a literature review rather
than empirical research itself. A third member of the abstraction team resolved discrepancies
regarding which studies to include.
4. Charting the data
The abstraction team consisted of eight of the authors. Two members of the abstraction team
reviewed each manuscript. Items abstracted included: type of review (consensus statement—a
comprehensive analysis by a panel of experts; systematic review—organized method of locat-
ing, assembling, and evaluating a body of literature; or non-systemic review—a narrative
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review of a body of literature but not systematically), cancer care continuum (based on the U.S.
National Cancer Institutes definitions: prevention, detection, diagnosis, treatment, survivor-
ship [19]), focus (general objective), research findings/recommendations, research/practice
gaps, and limitations. A third member of the abstraction team resolved discrepancies.
5. Collating, summarizing, and reporting the results
We include a descriptive numerical summary of the reviews and a qualitative thematic analysis
by the synthesis team to summarize findings across the cancer care continuum. The synthesis
team was divided into three groups focusing on: 1) cervical cancer; 2) breast cancer; and 3) gen-
eral themes. Each group reviewed the abstraction tables for themes separately and then the
entire team met and discussed the themes that emerged and how best to report the results. A
second round of data abstraction occurred after our synthesis meeting to capture more infor-
mation about the themes identified. We assessed whether studies were based on LMICs (pre-
dominantly, partially, little, none from LMIC settings), the geographical focus of the review
(global, LMIC, or a specific country), whether methods (e.g. strategy, terms, sources, inclusion/
exclusion criteria) were described clearly (yes, no). Finally to summarize and collate the topic
areas of each review, the abstraction team determined if a review focused on technological/
behavioral interventions and implementation science themes. Reviews were categorized by
topic based on if they reviewed studies regarding the theme, made recommendations based on
the theme, both, or neither. Reviews were labeled behavioral or technical intervention if the
authors assessed that the reviewed studies included an intervention design that focused either
on changing behaviors (e.g. education) or technical (e.g. technological innovation in screen-
ing). In determining a review’s consideration of implementation science, we judged the in-
clusion of four major themes relying on Peters et al, 2009 [20] and 2013 [21]: governance,
organizational-improvement, workforce capacity, and person- or community-centeredness
(Table 1).
Reporting in this analysis adheres to the PRISMA guidelines for reporting results of system-
atic reviews (S1 Table) [22]. PRISMA stands for Preferred Reporting Items for Systematic
Reviews and Meta-Analyses and is an evidence-based minimum set of items for reporting in
systematic reviews and meta-analyses. The aim of the PRISMA Statement is to help authors
improve the reporting of systematic reviews and meta-analyses.
6. Consultation
The manuscript was shared with the entire research team for feedback, insights, and editing.
Results
The search strategy implemented resulted in 62 reviews of cervical cancer and 34 reviews of
breast cancer in LMIC settings that met our eligibility criteria (Fig 1). Cervical and breast can-
cer reviews differed substantially (Table 2). The cervical cancer literature reflected a substan-
tially larger volume and distribution of both systematic [14, 23–40] and non-systematic
reviews [12, 41–80], while the breast cancer literature predominantly consisted of consensus
statements [81–102], with fewer systematic [103–108] or non-systematic [109–115] reviews.
The cervical cancer literature also contained three consensus statements [116–118].
Cervical cancer and breast cancer reviews also differed in their focus and content (Table 2).
Cervical cancer reviews focused more on prevention and detection, while breast cancer reviews
focused more on diagnosis, treatment, and survivorship, or more general aspects of all dimen-
sions. Few of the breast cancer reviews referenced research and data from LMICs themselves;
cervical cancer reviews were more likely to do so. Cervical cancer reviews were more globally
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focused, while breast cancer reviews focused more specifically on low-income regions. The
wide majority of reviews in both areas (breast and cervical cancer) did not present transparent
methods. Few studies reported even a subset of PRISMA elements [22].
Themes were identified if reviewed, recommended, or both, within a particular paper (Table 3).
Most reviews included both (recommended and reviewed) regarding technical and behavioral
interventions (Table 3). Frequently, reviews provided recommendations on a topic without first
presenting an analysis of the literature on that topic. For instance, cervical cancer reviews (Table 4)
Table 1. Implementation science themes.
Implementation
science theme
Key terms Example from reviews
Governance Policy, regulation, financing, public education, needs,
constraints, barriers, and partnerships




Implementation, quality improvement, quality assurance,
performance management, guidelines, and systems
strengthening.
“Where one or two dedicated staff had been designated to
manage the services (coordinating facility activities, managing
the screening itself, notifying women of test results, and
ensuring follow-up care), services functioned much more
effectively” [115].
Workforce capacity Training, continuing education, and peer learning “Health professional education should address surveillance for
breast cancer recurrence and second primary cancers,




Community empowerment, participation, information and
education, social marketing, community-managed services,
public health approaches, and community mobilization
“A key feature of a self-collected HPV testing strategy
(SC-HPV) is the move of the primary screening activities from
the clinic to the community” [24].
doi:10.1371/journal.pone.0134618.t001
Fig 1. PRISMA flow diagram for review of manuscripts.
doi:10.1371/journal.pone.0134618.g001
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tended to include recommendations around issues of governance and systems development. Simi-
larly, both cervical and breast cancer reviews (Table 5) included recommendations around work-
force capacity and person/community-centeredness. Breast cancer reviews (Table 3) were more
likely to include recommendations around topics actually reviewed in all themes.
Discussion
Development of the evidence base for best practice around breast and cervical cancer across
the cancer prevention-survivorship continuum is of primary importance to inform cancer con-
trol strategies in LMICs. In this scoping study, roughly twice as many reviews were identified
relating to cervical cancer compared with breast cancer in LMICs. While cervical cancer pre-
dominates in morbidity and mortality in some areas of the world (e.g. Sub-Saharan Africa),
overall breast cancer is more prevalent in LMICs than cervical cancer [14]. While systematic
reviews of the literature from LMICs around breast and cervical cancer is lacking overall, it is
particularly absent on breast cancer where only six systematic reviews were identified [16].
Evidence-based best practice arises from quality systematic reviews [118]. Production of
the evidence base for both breast and cervical cancer, however, faces considerable challenges.
Presently, most review papers addressing breast cancer in LMIC settings reflect consensus
statements, likely the result of a lack of research in LMICs from which to form systematic (or
Table 2. Descriptive summary of breast and cervical cancer reviews in low- andmiddle-income coun-
tries (LMICs).
Cervical cancer Breast cancer
n = 63 n = 36
n (%) n (%)
Type of reviews
Consensus statements 3 (5) 23 (64)
Systematic reviews 18 (29) 6 (17)
Non-systematic reviews 43 (68) 7 (19)
Cancer care continuum (categories not mutually exclusive)
Prevention 41 (65) 4 (11)
Detection 32 (51) 10 (28)
Diagnosis 15 (24) 10 (28)
Treatment 16 (25) 12 (33)
Survivorship 3 (5) 5 (14)
All 1 (2) 12 (33)
Data from LMIC
Predominantly (>80%) 22 (35) 6 (17)
Partially (30–<80%) 29 (46) 6 (17)
Little (1–<30%) 12 (19) 24(67)
Review focus on:
Global issues 18 (29) 1 (3)
LMIC 37 (59) 30 (83)
One region 3 (5) 2 (6)
One country 4 (6) 3 (8)
Methods clearly described
Yes 14 (22) 11 (31)
No 49 (78) 25 (69)
doi:10.1371/journal.pone.0134618.t002
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even non-systematic) reviews. The majority of reviews around breast cancer in LMICs are not
based on research generated from LMICs themselves, meaning that best practices and strate-
gies developed in high-income regions are forming the basis, through extrapolation and
perhaps erroneous assumption, for low-income regions. While most of the cervical cancer liter-
ature targeting LMICs considered for this scoping study reflected reviews that did include at
Table 3. Emerging thematic areas from breast and cervical cancer reviews in low- andmiddle-income
countries (LMICs).
Cervical cancer Breast cancer
n = 63 n = 36
n (%) n (%)
Technical/behavioral interventionsa
Both reviewed and recommended 42 (67) 33 (92)
Reviewed 7 (11) 0 (0)
Recommended 11 (17) 0 (0)
Neither 3 (5) 3 (8)
Governanceb
Both reviewed and recommended 19 (30) 16 (44)
Reviewed 2 (3) 0 (0)
Recommended 21 (33) 3 (8)
Neither 21 (33) 17 (47)
Systems developmentc
Both reviewed and recommended 15 (24) 15 (42)
Reviewed 4 (6) 0 (0)
Recommended 21 (33) 5 (14)
Neither 23 (37) 16 (44)
Workforce capacityd
Both reviewed and recommended 10 (16) 14 (39)
Reviewed 1 (2) 0 (0)
Recommended 11 (17) 6 (17)
Neither 41 (65) 16 (44)
Person/community centerednesse
Both reviewed and recommended 11 (17) 12 (33)
Reviewed 1 (2) 0 (0)
Recommended 8 (13) 3 (8)
Neither 43 (68) 21 (58)
Note: “Reviewed” indicates that the publication reviewed studies that pertained to this theme.
“Recommended” indicates that the publication presented recommendations on the given subject.
a Include reviews that assess technical or behavioral interventions
b Includes reviews that discuss policy, regulation, financing, public education, needs, constraints, barriers,
and partnerships.
c Includes reviews that discuss considerations of organizational improvement would have commented on
topics such as implementation, quality improvement, quality assurance, performance management,
guidelines, and systems strengthening.
d Includes reviews that discuss training, continuing education, and peer learning.
e includes reviews that discuss considerations of community empowerment, participation, information and
education, social marketing, community-managed services, public health approaches, and community
mobilization
doi:10.1371/journal.pone.0134618.t003
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Bradley et al. 2005 P LMIC X X X X X X
Jacob et al. 2005 T LMIC X X
Tangjitgamol et al. 2009 De, Di, T LMIC X X X X X X
SYSTEMATIC–
QUALITATIVE
Bello et al. 2011 P Region X X X X X X X
Chamot et al. 2010 T LMIC X X X X X
Cunningham et al. 2014 P Region X X X X X X X
Elit et al. 2011 De, T LMIC X X X X
Fesenfeld et al. 2013 P LMIC X X X X X
Gravitt et al. 2011 P, De, Di Global X X X X X
Katz et al. 2010 P LMIC X X X X X
McClung & Blumenthal 2012 T LMIC X
Rizvi et al. 2006 All Global X X X X
Sankaranarayanan
et al.
2006 De Global X X X X
Sankaranarayanan
et al.
2012 Di Global X X X
Tsu et al. 2005 P LMIC X X X X X
Williams-Brennan 2013 P LMIC X X X X X
SYSTEMATIC–
QUANTITATIVE
Arbyn et al. 2008 P LMIC X X X
Bradford & Goodman 2013 De LMIC X X
Cuzick et al 2008 P, De, Di, T Global X X X X X X X
Datta et al. 2006 Di, T, S Global X X X X
Forouzanfar et al 2011 P Global X X X
Sauvaget et al. 2011 P LMIC X X X
NON-SYSTEMATIC
Adefuye et al. 2013 P Region X X
Almonte et al. 2011 P, De Global X X X X X
Anorlu et al. 2007 De, Di, T LMIC X X
Batson et al. 2006 P Global X X X X X
Belinson et al. 2010 De LMIC X X X X X X
Bharadwaj et al. 2009 P Country X X X X X X
Bradford et al. 2013 P, De LMIC X X X
Bradley et al. 2006 De, T LMIC X X X X X
Chirenje 2005 All LMIC X X
Cronje 2005 P, De, Di, T Global X X X X
Cronje 2011 De LMIC X X X
Denny 2005 P, De, Di Global X X X X
Denny 2012 P, De, Di, T Global X X X X
Denny (Best Pract Res
Clin Obstet Gynaecol.)
2012 All Global X X X X
(Continued)
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least partial data generated from LMIC settings, most were not systematic reviews from which
to form summaries and recommendations. The majority of reviews included in each category
(breast and cervical) did not provide a transparent description of methods; hence, findings and
recommendations likely could be biased, or inappropriate, based on incomplete or non-repre-
sentative reviews of selected studies.
Without quality systematic reviews of breast and cervical cancer studies based on research
and data from LMICs themselves or why the evidence reviewed is thought to be applicable to
those countries, the evidence base will likely remain incomplete, poorly replicable, and poten-
tially recommending inaccurate and inappropriate strategies. Additionally, reviews (especially
in the cervical cancer literature) commonly over-reached the data evaluated and included rec-


























Denny et al. 2006 All LMIC X X X X X X
Garcia-Carranca and
Galvin
2007 P, De, Di Global X X X
Hoppenot et al. 2012 P, De, Di, T Global X X X X
Juneja et al. 2007 De Country X X X
Kane et al. 2012 P LMIC X X
Karimi Zarchi et al. 2009 P LMIC X X
Lowy et al. 2012 P LMIC X X
Luciani et al. 2009 P, De Global X X X X
Natunen et al. 2011 P LMIC X X X X
Parkhurst et al. 2013 P, De LMIC X X X X X
Patro et al. 2007 De Country X X X X X
Reeler et al. 2009 P, De LMIC X X X X X
Safaeian et al. 2007 De LMIC X X X X X
Sahasrabuddhe et al. 2011 P LMIC X X X X
Saleem et al. 2009 P LMIC X
Sankaranarayanan
et al.
2005 P, De LMIC X X X X
Sankaranarayanan
et al.
2006 De LMIC X X X X X
Sankaranarayanan
et al.
2009 P Global X X
Saxena et al. 2012 De Country X X X X
Sherris et al. 2005 De LMIC X X X
Stanley 2006 P LMIC X
Stanley 2007 P LMIC X X
Steben et al. 2012 P, De LMIC X X X X X X
Tomljenovic et al. 2013 P Global X
Tsu et al. 2012 P, De, Di, T LMIC X X X X
Woo et al. 2011 P LMIC X X X X X
Wright et al. 2012 P, De, Di, T LMIC X X X X X
a P = prevention, De = detection, Di = Diagnosis, T = Treatment, S = survivorship, All = all aspects
doi:10.1371/journal.pone.0134618.t004
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was concentrated mostly on issues of governance and systems development, essential compo-
nents of cancer control but frequently not the focus of empirical research [119].



























Anderson et al. 2006 All LMIC X
Anderson et al. 2015 All LMIC X X X
Anderson et al. 2008 All LMIC X
Anderson et al.
(Breast J).
2006 All LMIC X X X X X
Bese et al. 2008 T LMIC X X
Cardoso et al. 2013 T, S LMIC X X X X
Cleary et al. 2013 T LMIC X X
Corbex 2012 De LMIC X X
El Saghir et al 2008 T LMIC X
El Saghir et al. 2011 All LMIC X X X X
Enui et al. 2006 T LMIC X X X
Enui et al. 2008 T LMIC X
Ganz et al. 2013 S LMIC X X X X X
Harford et al. 2008 All LMIC X X
Harford et al. 2011 All LMIC X X X X X
Lodge & Corbex 2011 All LMIC X X X X X X
Masood et al. 2008 Di LMIC X
Shyyan et al. 2006 Di LMIC X X X X X
Shyyan et al.l 2008 All LMIC X X
Smith et al. 2006 De LMIC X X X X X
Wong et al 2009 T Region X X X
Yip et al. 2011 All LMIC X X X X X
Yip et al. 2008 All LMIC X X X X X
SYSTEMATIC
Asadzadeh et al 2011 P, De Country X X X X X X X
Chavarri-Guerra 2012 All Country X X X X X X X
El Saghir et al 2007 Di, S Region X X X X X X
Lee 2012 All Country X X X X X X
Patani et al. 2013 Di, T Global X X X
Zelle and Baltussen 2013 De, Di, T LMIC X X X X X X
NON-SYSTEMATIC
Al-Foheidi et al. 2013 De LMIC X X X X X
Kantelhardt et al. 2008 D, T LMIC X X X X
Keshtgar et al 2011 De, Di LMIC X X
Panieri 2012 De LMIC X X X
Romeiu 2011 P LMIC X
Shetty 2011 De, Di LMIC X X
Yip and Taib 2012 All LMIC X X X X X
a P = prevention, De = detection, Di = Diagnosis, T = Treatment, S = survivorship, All = all aspects
doi:10.1371/journal.pone.0134618.t005
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Areas of focus for the reviews included in this scoping study indeed reflect research priori-
ties to date around breast and cervical cancer. Largely because of rapid advances in HPV test-
ing, vaccination, and visual inspection, cervical cancer reviews are more focused on prevention
and detection than other phases of the continuum; in fact, only a few cervical cancer reviews
focused on survivorship. In contrast, breast cancer reviews were much less likely to focus on
prevention and more likely to focus upon treatment and survivorship, topics where more
global research has been completed. While the HPV vaccine has shifted the focus to prevention
in cervical cancer, mammography has yet to spark this type of shift in breast cancer [120]. In
terms of themes, most of the reviews for breast and cervical cancer address technical and
behavioral interventions, with far less focus on implementation science such as governance,
systems development, workforce capacity, and person- and community-centeredness
approaches.
This scoping study has limitations. First, with many similar assessments, the search strategy
could be incomplete and miss papers in other sources or that were not coded with keywords
used in this search. In a few instances, reviewers identified other papers not captured by the
original search strategy. Further, search terms may not have identified all reviews relevant to
LMIC but instead only those that deal with studies in LMIC. Second, our search identified
seven non-English studies that were not included in this review. Third, this study was not an
exhaustive search across gray literature and all databases for review materials on breast and cer-
vical cancer. In addition, gray literature was not the focus of this review only peer-reviewed
and indexed articles as we wanted to best understand the gaps in systematic reviews on breast
cancer and cervical cancer. Finally, our synthesis of the reviews was limited by the fact that
most reviews were non-systematic reviews in cervical cancer and with a notable proportion of
consensus statements in breast cancer without strong foundations in systematic methods. This
study’s strengths, however, include a systematic methodology, a large and interdisciplinary col-
laborating team, and the juxtaposition of breast and cervical cancer literature together creating
opportunity for comparison.
In order to provide evidence-based options in LMIC around cervical and breast cancer that
are scalable, research needs to arise from LMIC settings and needs to address implementation
science. Further research in low-resource settings rather than extrapolating from high-
resources settings is indicated by the scoping study, particularly around breast cancer control.
In addition, few of the reviews considered in this scoping study research include research that
draws from implementation science or makes recommendations based on implementation sci-
ence. Future research is needed across all implementation science themes, but workforce capac-
ity and community- or person-centeredness were especially under-considered in the reviews
included in this scoping study.
Demonstration is needed that shows existing therapies, diagnostic tests, and interventions
developed elsewhere can be as effective and practical in LMIC areas through implementation-
oriented research and assessments [121]. Complex technologies and therapies with demon-
strated effectiveness elsewhere typically require different implementation strategies in LMIC
regions [122–124], but can produce real population benefit [11]. Breast and cervical cancer
control in LMIC regions will likely remain suboptimal with excess morbidity and mortality
continually observed without LMIC-based systematic reviews of implementation strategies
that can generate evidence-based recommendations. As more and more technological advances
are made in both breast and cervical cancer control in LMICs, the issues around implementa-
tion science and systems development become even more critical to ensure access and appro-
priate resource allocation.
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